A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Recruiting

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(116 sites)

United States

Local Institution - 1029, Homewood, Alabama

Local Institution - 1044, Phoenix, Arizona

Local Institution - 1033, Encino, California

Local Institution - 1031, Irvine, California

ATP Clinical Research-302 W La Veta Ave, Orange, California